Pharma News

A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn’t respond to prior vaccination, according to the results of an international study led by a Weill Cornell Medicine investigator.

Imagine a world in which a vaccine is a cream you rub onto your skin instead of a needle a health care worker pushes into your one of your muscles. Even better, it’s entirely pain-free and not followed by fever, swelling, redness or a sore arm. No standing in a long line to get it. Plus, it’s cheap.

Academically, a pioneering healthcare EdTech company, proudly shares the exciting news of its students' exceptional performance in the final KAPS (Knowledge Assessment of Pharmaceutical Sciences) exam before transitioning to the OPRA (Overseas Pharmacists Readiness Assessment). Held on 25th November 2024, this final edition of the exam saw Academically students achieving a remarkable success rate of 90.51%.

Different types of cancer have unique molecular ‘fingerprints’ which are detectable in early stages of the disease and can be picked up with near-perfect accuracy by small, portable scanners in just a few hours, according to a study published today in the journal Molecular Cell.

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP). There were no safety concerns associated with tecovirimat.

Suven Pharmaceuticals Limited a technology-leading CDMO specializing in complex and innovative drug modalities, has announced the acquisition of a controlling stake in NJ Bio Inc. with an investment of  USD 64.4 million.